AceRNA Technologies is a biotech startup that develops patient-centric genetic therapies with RNA switch technology for drug discovery.
AceRNA Technologies has raised $6.2M in total funding. The most recent round was Series B. The last funding was announced in May 2024.
AceRNA Technologies's investors include Mitsubishi UFJ Capital, SMBC Venture Capital, UTokyo Innovation Platform, Kyoto University Innovation Capital, DCI Partners.
AceRNA Technologies is headquartered in Kyoto, Japan.
AceRNA Technologies is a biotech startup that develops patient-centric genetic therapies with RNA switch technology for drug discovery.
AceRNA Technologies is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AceRNA Technologies — Funding & Investors." VCBacked, May 7, 2024, https://www.vcbacked.co/company/acerna-technologies. Accessed August 14, 2026.
VCBacked. (2024). AceRNA Technologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/acerna-technologies
{{cite web |title=AceRNA Technologies — Funding & Investors |url=https://www.vcbacked.co/company/acerna-technologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated